- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06667908
Um estudo de JNJ-90301900 em combinação com quimiorradiação seguida de imunoterapia de consolidação para câncer de pulmão de células não pequenas (NSCLC) (CONVERGE)
Um estudo de fase 2, randomizado, aberto e com controle ativo de JNJ-90301900 em combinação com quimiorradiação seguida de durvalumabe em NSCLC de estágio III localmente avançado e irressecável
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Study Contact
- Número de telefone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Locais de estudo
-
-
-
Camperdown, Austrália, 2050
- Recrutamento
- Chris O'Brien Lifehouse
-
Herston, Austrália, 4029
- Recrutamento
- Royal Brisbane and Women's Hospital
-
Nedlands, Austrália, 6009
- Recrutamento
- Sir Charles Gairdner Hospital
-
North Ryde, Austrália, 2109
- Recrutamento
- Macquarie University
-
Parkville, Austrália, 3050
- Recrutamento
- Royal Melbourne Hospital
-
-
-
-
-
Barretos, Brasil, 14784 400
- Recrutamento
- Fundacao Pio XII
-
São Paulo, Brasil, 05651 901
- Recrutamento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 01308 050
- Recrutamento
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
-
-
-
-
Dongguan, China, 523109
- Recrutamento
- Dongguan People s Hospital
-
Guangzhou, China, 510080
- Recrutamento
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, China, 250117
- Recrutamento
- The Affiliated Cancer Hospital of Shandong First Medical University
-
-
-
-
-
Madrid, Espanha, 28041
- Recrutamento
- Hosp. Univ. 12 de Octubre
-
Pamplona, Espanha, 31008
- Recrutamento
- Clinica Univ. de Navarra
-
Santiago de Compostela, Espanha, 15706
- Recrutamento
- Hosp. Clinico Univ. de Santiago
-
Valencia, Espanha, 46026
- Recrutamento
- Hosp. Univ. I Politecni La Fe
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Recrutamento
- Moores Cancer Center at UC San Diego Health
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos, 06030
- Concluído
- University of Connecticut Health Center
-
New Haven, Connecticut, Estados Unidos, 06519
- Recrutamento
- Yale University
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Recrutamento
- University of Miami
-
Orlando, Florida, Estados Unidos, 32806
- Recrutamento
- Orlando Health Cancer Institute
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30306
- Recrutamento
- Emory University Winship Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Beth Israel Deaconess Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63130
- Recrutamento
- Washington University in St Louis
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- NYU Langone Health
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Recrutamento
- University of North Carolina at Chapel Hill
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Recrutamento
- FirstHealth of the Carolinas
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Recrutamento
- University Hospitals Cleveland Medical Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Recrutamento
- Oregon Health And Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- MD Anderson Cancer Center
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05401
- Recrutamento
- University of Vermont Medical Center
-
-
-
-
-
Brest, França, 29200
- Recrutamento
- Hopital De La Cavale Blanche
-
Marseille, França, 13015
- Recrutamento
- Hopital Nord Marseille
-
Paris, França, 75248
- Recrutamento
- Institut Curie
-
Paris, França, 75020
- Recrutamento
- Hopital Tenon
-
Rouen, França, 76000
- Recrutamento
- CHU Rouen Hopital Charles Nicolle
-
Villejuif, França, 94805
- Recrutamento
- Gustave Roussy
-
-
-
-
-
Amsterdam, Holanda, 1066 CX
- Recrutamento
- Antoni van Leeuwenhoek
-
Nijmegen, Holanda, 6525 GA
- Recrutamento
- Radboud Umcn
-
-
-
-
-
Shatin, Hong Kong
- Recrutamento
- Prince of Wales Hospital
-
-
-
-
-
London, Reino Unido, NW1 2BU
- Recrutamento
- University College London Hospitals
-
-
-
-
-
Istanbul, Turquia (Türkiye), 34899
- Recrutamento
- Marmara University Pendik Training Hospital
-
Sakarya, Turquia (Türkiye), 54100
- Recrutamento
- Sakarya University Training and Research Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening
- Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment/randomization
- Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification
- Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) per RECIST version 1.1 that is amenable to intratumoral and/or intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion Criteria:
- Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression
- Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV
- Another concurrent or prior primary malignancy within the last 36 months at informed consent
- Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab
- History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part 1: Cohort A and Cohort B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (cohort A: 22% gross tumor volume [GTV] and cohort B: 33% GTV) along with cCRT (concurrent chemotherapy with radiation therapy) followed by consolidation immunotherapy (cIT) to evaluate feasibility of JNJ-90301900 injection procedure. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Experimental: Part 2: Arm A and Arm B
Participants will receive JNJ-90301900 injected intratumorally and/or intranodally (Arm A: 22% GTV and Arm B: 33% GTV) along with cCRT followed by cIT to evaluate the efficacy and safety of JNJ-90301900. |
JNJ-90301900 will be injected intratumorally and/or intranodally. Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
|
Comparador Ativo: Part 2: Arm C: (Control treatment)
Participants will receive treatment with cCRT followed by cIT as control treatment to evaluate the efficacy and safety of JNJ-90301900. |
Durvalumab will be administered as intravenous (IV) infusion as cIT. Radiation by intensity modulated radiation therapy (IMRT) will be administered. Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy. Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR) Using Independent Central Review (ICR) Assessment
Prazo: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 using ICR assessments. |
Up to 2 Years and 2 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR) Post-cCRT and Pre-cIT
Prazo: Up to 12 Weeks
|
Objective response rate is defined as percentage of participants who achieve CR or PR, post-concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) and pre-consolidation immunotherapy (cIT) based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Disease Control Rate (DCR) Post-cCRT and Pre-cIT
Prazo: Up to 12 Weeks
|
DCR is defined as percentage of participants who achieve CR, PR and stable disease post-cCRT and pre-cIT based on investigator's assessment according to RECIST v1.1. |
Up to 12 Weeks
|
|
Objective Response Rate (ORR) as Assessed by the Investigator
Prazo: Up to 2 Years and 2 months
|
ORR is defined as the percentage of participants who have a best response of CR or PR using RECIST v1.1 as assessed by the investigator. |
Up to 2 Years and 2 months
|
|
Progression Free Survival (PFS)
Prazo: Up to 2 Years and 2 months
|
PFS is defined as the time from the enrollment/randomization until disease progression or death due to any cause according to RECIST v1.1. |
Up to 2 Years and 2 months
|
|
Duration of Response (DoR)
Prazo: Up to 2 Years and 2 months
|
DoR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 2 Years and 2 months
|
|
Time to Locoregional Failure (LRF)
Prazo: Up to 2 Years and 2 months
|
Time to LRF is defined as the time from enrollment/randomization to the first LRF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Time to Distant Failure (DF)
Prazo: Up to 2 Years and 2 months
|
Time to DF is defined as the time from enrollment/randomization to the first DF using ICR assessments. |
Up to 2 Years and 2 months
|
|
Number of Participants with Treatment-Emergent Adverse Event (TEAE) Related to Study Treatment
Prazo: Up to 2 Years and 2 months
|
TEAE is defined as any new or worsening adverse event (AE) occurring at or after the initial administration of study treatment through the day of last dose of study treatment received plus 30 days or prior to the start of subsequent anticancer therapy (non-durvalumab), whichever is earlier, or any follow-up AE with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent anticancer therapy, or any AE that is considered treatment-related regardless of the start date of the event. TEAEs related to JNJ-90301900 injection procedure, JNJ-90301900, RT, ChT, or cIT will be reported. |
Up to 2 Years and 2 months
|
|
Number of Participants Reporting Laboratory Parameters, Physical Examination, Vital Signs Including Eastern Cooperative Oncology Group (ECOG) Performance Status Abnormalities
Prazo: Up to 2 Years and 2 months
|
Participants with laboratory parameters, physical examination, vital signs including ECOG performance status abnormalities will be reported. |
Up to 2 Years and 2 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 90301900NSC2001
- 90301900NSC2001 (Outro identificador: Janssen Research & Development, LLC)
- 2024-518276-32-00 (Identificador de registro: EUCT number)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .